Skip to main content
. 2022 Jun 20;12:873709. doi: 10.3389/fonc.2022.873709

Table 2.

Incidence of ILD progression during frst-line chemotherapy.

Regimens Antiangiogenic group Control Group P Value
Number ProgressN (%) Number ProgressN (%)
AP 7 0 (0) 17 3 (17.7)
GP 9 0 (0) 10 2 (20)
TP 2 (0) 2 0 (0)
PEM 4 0 (0) 1 1 (100)
All 22 0 (0) 30 6 (20) 0.033
Including PEM scheme 11 0 (0) 18 4 (22.2) 0.268

AP, pemetrexed+cisplatin; GP, gemcitabine+cisplatin; TP, nano albumin paclitaxel+platinum; PEM, pemetrexed.